Aogi, Kenjiro
Takeuchi, Hideki
Saeki, Toshiaki http://orcid.org/0000-0002-8893-9519
Aiba, Keisuke
Tamura, Kazuo
Iino, Keiko
Imamura, Chiyo K.
Okita, Kenji
Kagami, Yoshikazu
Tanaka, Ryuhei
Nakagawa, Kazuhiko
Fujii, Hirofumi
Boku, Narikazu
Wada, Makoto
Akechi, Tatsuo
Iihara, Hirotoshi
Ohtani, Shoichiro
Okuyama, Ayako
Ozawa, Keiko
Kim, Yong-Il
Sasaki, Hidenori
Shima, Yasuo
Takeda, Masayuki
Nagasaki, Eijiro
Nishidate, Toshihiko
Higashi, Takahiro
Hirata, Kouichi
Funding for this research was provided by:
JSCO
Article History
Received: 6 August 2020
Accepted: 16 October 2020
First Online: 8 November 2020
Compliance with ethical standards
:
: Aogi Kenjiro received lecture fees from Taiho Pharmaceutical Co., Ltd./Ono Pharmaceutical Co., Ltd. and research funding from Chugai Pharmaceutical Co., Ltd. Saeki Toshiaki received lecture fees from Ono Pharmaceutical Co., Ltd./Taiho Pharmaceutical Co., Ltd. Tamura Kazuo received lecture fees from SymBio Pharmaceuticals Limited./AC Medical Co., Ltd. Nakagawa Kazuhiko received lecture fees from AstraZeneca K.K./Astellas Pharma Inc./MSD K.K./Ono Pharmaceutical Co., Ltd./Nippon Boehringer Ingelheim Co., Ltd./Novartis Pharma K.K./Pfizer Japan Inc./Clinical Trial Co., Ltd./Medicus Shuppan, Publishers Co., Ltd./Care Net, Inc./Reno. Medical K.K./Kyorin Pharmaceutical Co., Ltd./Medical Review Co., Ltd./Roche Diagnostics K.K./Bayer Yakuhin, Ltd./Medical Mobile Communications Co., Ltd./3H Clinical Trial Inc./Nichi-Iko Pharmaceutical Co., Ltd./Takeda Pharmaceutical Co., Ltd./Taiho Pharmaceutical Co., Ltd./Bristol Myers Squibb Company/Eli Lilly Japan K.K./SymBio Pharmaceuticals Limited./Chugai Pharmaceutical Co., Ltd./Nanzando Co., Ltd./Yodosha Co., LTD./Nikkei Business Publications, Inc./Daiichi Sankyo Co., Ltd./Thermo Fisher Scientific K.K./Yomiuri Telecasting Corporation/Nippon Kayaku Co., Ltd./Merck Biopharma Co., Ltd./AbbVie Inc. and research funding from MSD K.K./A2 Healthcare Corp./inVentiv Health Japan/Astellas Pharma Inc./Daiichi Sankyo Co., Ltd./Novartis Pharma K.K./AbbVie Inc./Quintiles Inc./IQVIA Services Japan K.K./ICON Japan K.K./Chugai Pharmaceutical Co., Ltd./Takeda Pharmaceutical Co., Ltd./EP-CRSU Co., Ltd./Oncology Inc./Linical Co., Ltd./Eli Lilly Japan K.K./Co., Ltd./Bristol Myers Squibb Company/Nippon Boehringer Ingelheim Co., Ltd./Taiho Pharmaceutical Co., Ltd./Japan Inc./International Corp./SymBio Pharmaceuticals Limited/Ono Pharmaceutical Co., Ltd./Merck Serono Co., Ltd./Merck Biopharma Co., Ltd./AstraZeneca K.K./CMIC Shift Zero K.K./Pharmaceutical Co., Ltd./Kyowa Hakko Kirin Co., Ltd./EPS Corporation./Bayer Yakuhin, Ltd./Syneos Health./EPS International Co., Ltd./Pfizer R&D Japan G.K./Otsuka Pharmaceutical Co., Ltd. and consulting or advisory fees from Takeda Pharmaceutical Co., Ltd./Kyorin Pharmaceutical Co., Ltd./Ono Pharmaceutical Co., Ltd./Pfizer Japan Inc./Eli Lilly Japan K.K. Boku Narikazu received lecture fees from Taiho Pharmaceutical Co., Ltd./Ono Pharmaceutical Co., Ltd./Bristol-Myers Squibb Company and research funding from Ono Pharmaceutical Co., Ltd./Taiho Pharmaceutical Co., Ltd./Takeda Pharmaceutical Co., Ltd. Iihara Hirotoshi received research funding from Ono Pharmaceutical Co., Ltd. Ohtani Shoichiro received lecture fees from Chugai Pharmaceutical Co., Ltd./Eisai Co., Ltd./Eli Lilly Japan K.K./Pfizer Japan Inc./AstraZeneca K.K. Takeda Masayuki received lecture fees from Nippon Boehringer Ingelheim Co., Ltd./Chugai Pharmaceutical Co., Ltd./AstraZeneca K.K./Ono Pharmaceutical Co., Ltd./Novartis Pharma K.K. The rest of the authors have no conflicts of interest.